NasdaqCM:SLNOBiotechs
A Look At Soleno Therapeutics (SLNO) Valuation After Analyst Upgrades On VYKAT XR And Prader Willi Program
Soleno Therapeutics (SLNO) is back in focus after recent analyst reports pointed to stronger than expected early sales of its newly commercialized VYKAT XR, solid new patient starts, and interest in its Prader Willi Syndrome program.
See our latest analysis for Soleno Therapeutics.
Even with the recent analyst enthusiasm around VYKAT XR and the Prader Willi program, Soleno’s 30 day share price return of 9.37% and year to date share price return decline of 18.38%, alongside a 1 year total...